ATP-Citrate Lyase: A Prognostic Marker of Non-Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population

IF 2.7 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cell Biochemistry and Function Pub Date : 2025-08-18 DOI:10.1002/cbf.70109

Kanika Phutela, Navneet Singh, Amanjit Bal, Harkant Singh, Jyotdeep Kaur, Sadhna Sharma

{"title":"ATP-Citrate Lyase: A Prognostic Marker of Non-Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population","authors":"Kanika Phutela, Navneet Singh, Amanjit Bal, Harkant Singh, Jyotdeep Kaur, Sadhna Sharma","doi":"10.1002/cbf.70109","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Tissue biopsies are routinely used for identifying driver mutations in tumors but limitations such as tumor heterogeneity have encouraged the use of liquid biopsies for the identification of new biomarkers. ATP-citrate lyase (ACLY) has been recognized as a potential target for tumor inhibition due to its overexpression in several cancers. However, the clinical significance of this enzyme remains unknown in liquid biopsies. In this study, 31 pleural effusion fluid samples were collected from patients suspected of malignancy for analyzing the gene expression of ACLY and associated metabolic enzymes. Gene expression profiling by RT-PCR revealed significantly increased ACLY mRNA levels along with other metabolic enzymes (FASN, ACC, CS, and ICD1) in malignant lung adenocarcinoma pleural fluid samples indicating that ACLY plays a critical role in the progression of lung adenocarcinoma. This study identified the potential of using metabolic enzymes as biomarkers in identification of lung adenocarcinoma patients. The observations highlighted the significance of lipogenic enzymes mainly ACLY and fatty acid synthase as diagnostic markers in lung adenocarcinoma liquid biopsies.</p></div>","PeriodicalId":9669,"journal":{"name":"Cell Biochemistry and Function","volume":"43 8","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biochemistry and Function","FirstCategoryId":"99","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/cbf.70109","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tissue biopsies are routinely used for identifying driver mutations in tumors but limitations such as tumor heterogeneity have encouraged the use of liquid biopsies for the identification of new biomarkers. ATP-citrate lyase (ACLY) has been recognized as a potential target for tumor inhibition due to its overexpression in several cancers. However, the clinical significance of this enzyme remains unknown in liquid biopsies. In this study, 31 pleural effusion fluid samples were collected from patients suspected of malignancy for analyzing the gene expression of ACLY and associated metabolic enzymes. Gene expression profiling by RT-PCR revealed significantly increased ACLY mRNA levels along with other metabolic enzymes (FASN, ACC, CS, and ICD1) in malignant lung adenocarcinoma pleural fluid samples indicating that ACLY plays a critical role in the progression of lung adenocarcinoma. This study identified the potential of using metabolic enzymes as biomarkers in identification of lung adenocarcinoma patients. The observations highlighted the significance of lipogenic enzymes mainly ACLY and fatty acid synthase as diagnostic markers in lung adenocarcinoma liquid biopsies.

Abstract Image

查看原文本刊更多论文

atp -柠檬酸裂解酶：非小细胞肺癌的预后标记物指示了印度人群腺癌的进展

组织活检通常用于识别肿瘤中的驱动突变，但肿瘤异质性等局限性鼓励使用液体活检来识别新的生物标志物。atp -柠檬酸裂解酶（ACLY）已被认为是肿瘤抑制的潜在靶点，因为它在几种癌症中过表达。然而，这种酶在液体活检中的临床意义尚不清楚。本研究收集31例疑似恶性肿瘤患者的胸腔积液样本，分析ACLY及相关代谢酶的基因表达。RT-PCR基因表达谱显示，ACLY mRNA水平与其他代谢酶（FASN、ACC、CS和ICD1）在恶性肺腺癌胸膜液样本中显著升高，表明ACLY在肺腺癌的进展中起关键作用。本研究确定了使用代谢酶作为识别肺腺癌患者的生物标志物的潜力。这些观察结果强调了脂肪生成酶（主要是ACLY）和脂肪酸合成酶作为肺腺癌液体活检诊断标志物的意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Biochemistry and Function 生物-生化与分子生物学

CiteScore

6.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Cell Biochemistry and Function publishes original research articles and reviews on the mechanisms whereby molecular and biochemical processes control cellular activity with a particular emphasis on the integration of molecular and cell biology, biochemistry and physiology in the regulation of tissue function in health and disease. The primary remit of the journal is on mammalian biology both in vivo and in vitro but studies of cells in situ are especially encouraged. Observational and pathological studies will be considered providing they include a rational discussion of the possible molecular and biochemical mechanisms behind them and the immediate impact of these observations to our understanding of mammalian biology.